Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine

•One dose of AdtA24 + adjuvant prevented clinical FMD at 7 and 14 dpv.•AdtA24 + adjuvant improved protection for FMD and viremia vs. a 4× AdtA24 dose alone.•AdtA24 + adjuvant enhanced the FMDV neutralization titer vs. a 4× AdtA24 dose alone.•AdtA24 + adjuvant dosed 7 or 14 days before FMDV exposure...

Ausführliche Beschreibung